Apogee Therapeutics, Inc. Common Stock (APGE NASDAQ) stock market data APIs
$47.2474
-2.91(-6.2%)
as of July 3, 2025
Try our APIs with
free plan!
Apogee Therapeutics, Inc. Common Stock Financial Data Overview
Price chart is built with
Anychart
Apogee Therapeutics, Inc., a clinical stage biotechnology company, develops novel biologics for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other inflammatory and immunology indications. The company develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for the treatment of AD, which is in phase 2 clinical trials; and for the treatment of asthma and EoE which is in phase 1 clinical trial. It also develops APG279 that is in preclinical stage for the treatment of AD; APG990, an SQ extended half-life mAb for the treatment of AD; APG333, a human mAb against thymic stromal lymphopoietin for the treatment of asthma and COPD; and APG808, an SQ extended half-life mAb targeting IL-4Ra for the treatment of Type 2 allergic diseases. Apogee Therapeutics, Inc. was incorporated in 2022 and is headquartered in Waltham, Massachusetts.
Prev. Close
47.2474
Open
44.3423
High
47.984
Low
43.0798
52 wk Range
26.2-63.5
Market Cap
2 768 M
Shares Outstanding
44 826 K
EPS
-0.95
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Apogee Therapeutics, Inc. Common Stock data using free add-ons & libraries
Get Apogee Therapeutics, Inc. Common Stock Fundamental Data
Apogee Therapeutics, Inc. Common Stock Fundamental data includes:
- Net Revenue:
- EBITDA: -241 418 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-05-12
- EPS/Forecast: -0.58
Get Apogee Therapeutics, Inc. Common Stock End-of-day data
EOD Historical Data package for
$
19.99
/mo.
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Apogee Therapeutics, Inc. Common Stock News
New
Apogee Therapeutics stock maintains buy rating at Stifel ahead of data
Investing.com - Stifel reiterated its buy rating and $95.00 price target on Apogee (NASDAQ:APOG) Therapeutics Inc (NASDAQ:APGE), currently trading at $41.18 with a market cap of $2.4 billion, ahead of...
APGE Makes Bullish Cross Above Critical Moving Average
In trading on Friday, shares of Apogee Therapeutics Inc (Symbol: APGE) crossed above their 200 day moving average of $43.86, changing hands as high as $44.64 per share. Apogee Therapeutics Inc shares...
Wall Street Analysts See a 129.09% Upside in Apogee Therapeutics Inc. (APGE): Can the Stock Really Move This High?
Shares of Apogee Therapeutics Inc. (APGE) have gained 9.9% over the past four weeks to close the last trading session at $40.98, but there could still be a solid upside left in the stock if short-term...
Apogee Therapeutics to Participate at the Jefferies Global Healthcare Conference
SAN FRANCISCO and BOSTON, May 29, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq: APGE), today announced that members of management will participate in a fireside chat at the Jefferies ...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
